Skip to Main Content
Table 2—

Changes in weight and risk factors during the study

Time−2 months0 months18 months36 monthsP value
Weight (kg) 111.9 ± 16.0 −14.3 (−12) −9.6 (8.4) −7.2 (−6.3) 0.028 
 110.7 ± 17.9 −14.5 (−13) −11.7 (10.4) −9.4 (−8.3)  
Waist circumference (cm) 119 ± 10.9 −12 −9 −5.4 0.032 
 119 ± 12.1 −12 −12 −7.7  
A1C (%) 6.28 ± 0.64 −0.48 −0.34 −0.51 NS 
 6.32 ± 0.93 −0.54 −0.43 −0.69  
Fasting glucose (mmol/l) 6.27 ± 1.54 −0.95 −0.45 −0.32 NS 
 6.44 ± 1.83 −1.1 −0.67 −0.49  
Fasting insulin (pmol/l) 114 ± 58.3 −45 −28 −12 NS 
 116 ± 65.3 −48 −35 −26  
C-peptid (nmnol/l) 1.02 ± 0.39 −0.19 −0.03 +0.16 0.09 
 1.10 ± 0.43 −0.21 −0.1 +0.05  
Total cholesterol (mmol/l) 6.02 ± 1.08 −1.2 −0.13 −0.46 NS 
 5.91 ± 1.26 −1.2 −0.36 −0.46  
LDL cholesterol (mmol/l) 3.77 ± 0.94 −0.80 −0.12 −0.38 NS 
 3.71 ± 1.04 −0.75 −0.29 −0.34  
HDL cholesterol (mmol/l) 1.15 ± 0.26 −0.07 +0.11 +0.06 NS 
 1.13 ± 0.26 −0.05 +0.06 +0.04  
Triglycerides (mmol/l) 2.50 ± 1.41 −0.94 −0.34 −0.43 NS 
 2.36 ± 1.24 −0.89 −0.32 −0.38  
BT sys (mmHg) 144 ± 17.3 −12 −7.2 −8.2 NS 
 144 ± 19.3 −13 −8.2 −7.8  
BT dia (mmHg) 90.7 ± 10.4 −7.6 −4.8 −4.7 NS 
 90.8 ± 11.6 −7.2 −5.1 −3.7  
Time−2 months0 months18 months36 monthsP value
Weight (kg) 111.9 ± 16.0 −14.3 (−12) −9.6 (8.4) −7.2 (−6.3) 0.028 
 110.7 ± 17.9 −14.5 (−13) −11.7 (10.4) −9.4 (−8.3)  
Waist circumference (cm) 119 ± 10.9 −12 −9 −5.4 0.032 
 119 ± 12.1 −12 −12 −7.7  
A1C (%) 6.28 ± 0.64 −0.48 −0.34 −0.51 NS 
 6.32 ± 0.93 −0.54 −0.43 −0.69  
Fasting glucose (mmol/l) 6.27 ± 1.54 −0.95 −0.45 −0.32 NS 
 6.44 ± 1.83 −1.1 −0.67 −0.49  
Fasting insulin (pmol/l) 114 ± 58.3 −45 −28 −12 NS 
 116 ± 65.3 −48 −35 −26  
C-peptid (nmnol/l) 1.02 ± 0.39 −0.19 −0.03 +0.16 0.09 
 1.10 ± 0.43 −0.21 −0.1 +0.05  
Total cholesterol (mmol/l) 6.02 ± 1.08 −1.2 −0.13 −0.46 NS 
 5.91 ± 1.26 −1.2 −0.36 −0.46  
LDL cholesterol (mmol/l) 3.77 ± 0.94 −0.80 −0.12 −0.38 NS 
 3.71 ± 1.04 −0.75 −0.29 −0.34  
HDL cholesterol (mmol/l) 1.15 ± 0.26 −0.07 +0.11 +0.06 NS 
 1.13 ± 0.26 −0.05 +0.06 +0.04  
Triglycerides (mmol/l) 2.50 ± 1.41 −0.94 −0.34 −0.43 NS 
 2.36 ± 1.24 −0.89 −0.32 −0.38  
BT sys (mmHg) 144 ± 17.3 −12 −7.2 −8.2 NS 
 144 ± 19.3 −13 −8.2 −7.8  
BT dia (mmHg) 90.7 ± 10.4 −7.6 −4.8 −4.7 NS 
 90.8 ± 11.6 −7.2 −5.1 −3.7  

Data are n (%) or means ± SD. The abdominally obese subjects were randomised after 2 months of VLED (from month −2 to month 0) to receive either orlistat (O) or placebo (P). Values at the various times are absolute changes from initial values (month −2) calculated from the intention-to-treat population. Minus indicates reduction from initial values and plus increment. Body weight changes are also given in percentage (in parentheses). P values are given for the absolute changes after 36 months between orlistat and placebo. The time effect at 36 months versus 0 month is significant for all parameters (P < 0.001).

Close Modal

or Create an Account

Close Modal
Close Modal